Compare Dolby Laboratories, Inc. (DLB) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Koninklijke Philips NV — how do they compare? Dolby Laboratories, Inc. trades at $61.2 (market cap $5.82B), while Koninklijke Philips NV trades at $27.09 (market cap $26.33B). The key difference: Koninklijke Philips NV is far larger — about 4.5× Dolby Laboratories, Inc.'s market cap, and Koninklijke Philips NV pays the higher dividend (3.76%). Which is the better fit depends on your goals.
| DLB | PHG | |
|---|---|---|
Market Cap | $5.82B | $26.33B |
Sector | Industrials | Health |
52-Week High | $75.62 | $32.91 |
52-Week Low | $48.51 | $25.02 |
Enterprise Value | $5.19B | $32.89B |
Dividend Yield | 2.32% | 3.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $61.77, up 1.4% today, with a bullish technical trend and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, including Q2 2026 EPS of $0.69 versus $0.67 expected. Revenue remains stable around $1.3 billion annually, with robust gross margins of 87.61%. Recent news highlights growth in Dolby Atmos and automotive licensing, though near-term revenue volatility persists.
DLB offers a compelling valuation with a P/E of 26.29 below the analyst target of $87.50, implying significant upside. Key risks include licensing deal timing and competitive pressures in audio-video tech. Institutional sentiment is positive, with 47% of analysts rating it a Buy, but investors should monitor execution on Q4 growth guidance.
PHG trades at $26.73, up 1.52% today, with a bullish technical signal and recent earnings beats in Q4 2025, Q1 2026, and Q2 2026. The company reported $17.83B revenue and $895M net income for 2025, with a P/E of 20.29 and net margin of 6.31%. Recent news highlights Exor increasing its stake and FDA clearances for new health tech products, supporting positive sentiment.
Outlook is cautiously optimistic with strong profitability and institutional interest, but risks include order intake volatility and debt levels. Analysts show 40.9% buy ratings, indicating potential upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
